GNCA · Genocea Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.44M | - | $9.47M | $10.51M | $8.75M | - | $7.55M | $8.59M | $9.99M | - |
| SG&A | $3.60M | - | $3.88M | $4.03M | $3.67M | - | $3.64M | $3.48M | $3.39M | - |
| Total Operating Expenses | $16.04M | - | $13.36M | $14.55M | $12.42M | - | $11.19M | $12.07M | $13.38M | - |
| D&A | $400.0K | - | - | - | $381.0K | - | - | - | $276.0K | - |
| Operating Income | ($15.77M) | - | ($11.72M) | ($14.55M) | ($12.42M) | - | ($10.74M) | ($11.16M) | ($13.38M) | - |
| Interest Expense | $231.0K | - | $290.0K | $282.0K | $279.0K | - | $377.0K | $365.0K | $259.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($15.98M) | - | ($3.62M) | ($4.31M) | ($11.98M) | - | ($4.55M) | ($11.32M) | ($12.85M) | - |
| EPS - Basic | ($0.22) | - | ($0.05) | ($0.39) | ($0.46) | - | ($0.08) | - | - | - |
| EPS - Diluted | ($0.22) | - | ($0.05) | ($0.39) | ($0.46) | - | ($0.26) | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.14M | $37.15M | $48.91M | $60.40M | $66.03M | $79.77M | $87.63M | $22.11M | $26.51M | $40.13M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $594.0K | $500.0K | $978.0K | $1.36M | $1.03M | $534.0K | $567.0K | $678.0K | $860.0K | $553.0K |
| Current Assets | $24.41M | $41.82M | $50.61M | $62.91M | $68.82M | $82.23M | $90.33M | $24.67M | $29.07M | $41.58M |
| Total Assets | $38.79M | $55.97M | $64.92M | $77.38M | $83.94M | $98.49M | $106.20M | $40.52M | $45.19M | $52.61M |
| Current Liabilities | $18.03M | $18.68M | $14.70M | $14.83M | $11.42M | $25.00M | $23.82M | $21.52M | $14.66M | $6.28M |
| Long-term Debt | $2.95M | $4.15M | $5.33M | $6.49M | $7.65M | $0 | $0 | $0 | $5.82M | $13.41M |
| Total Liabilities | $26.40M | $28.89M | $27.09M | $73.33M | $82.18M | $89.51M | $85.99M | $32.48M | $32.18M | $27.57M |
| Stockholders' Equity | $12.38M | $27.07M | $37.83M | $4.05M | $1.76M | $8.98M | $20.20M | $8.04M | $13.01M | $25.04M |
| Retained Earnings | ($423.84M) | ($407.86M) | ($394.58M) | ($390.96M) | ($386.65M) | ($374.67M) | ($359.68M) | ($355.13M) | ($343.81M) | ($330.95M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.21M) | - | - | - | ($12.39M) | - | - | - | ($13.80M) | - |
| Investing Cash Flow | ($939.0K) | - | - | - | ($1.04M) | - | - | - | ($217.0K) | - |
| Financing Cash Flow | ($863.0K) | - | - | - | ($297.0K) | - | - | - | $395.0K | - |
| CapEx | $961.0K | - | - | - | $1.11M | - | - | - | $233.0K | - |
| Free Cash Flow | ($16.17M) | - | - | - | ($13.50M) | - | - | - | ($14.03M) | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.01 | - | - | - | 1.13 | - | - | - | 1.09 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -41.2% | - | -5.6% | -5.6% | -14.3% | - | -4.3% | -27.9% | -28.4% | - |
| Return on equity | -129.0% | - | -9.6% | -106.3% | -680.1% | - | -22.5% | -140.9% | -98.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.35 | 2.24 | 3.44 | 4.24 | 6.02 | 3.29 | 3.79 | 1.15 | 1.98 | 6.62 |
| Quick ratio | 1.35 | 2.24 | 3.44 | 4.24 | 6.02 | 3.29 | 3.79 | 1.15 | 1.98 | 6.62 |
| Cash ratio | 1.12 | 1.99 | 3.33 | 4.07 | 5.78 | 3.19 | 3.68 | 1.03 | 1.81 | 6.39 |
| Leverage | ||||||||||
| Debt / Equity | 0.24 | 0.15 | 0.14 | 1.60 | 4.34 | 0.00 | 0.00 | 0.00 | 0.45 | 0.54 |
| Debt / Assets | 0.08 | 0.07 | 0.08 | 0.08 | 0.09 | 0.00 | 0.00 | 0.00 | 0.13 | 0.25 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -68.3x | - | -40.4x | -51.6x | -44.5x | - | -28.5x | -30.6x | -51.6x | - |
| Equity multiplier | 3.13 | 2.07 | 1.72 | 19.08 | 47.64 | 10.97 | 5.26 | 5.04 | 3.47 | 2.10 |
| Liabilities / Assets | 0.68 | 0.52 | 0.42 | 0.95 | 0.98 | 0.91 | 0.81 | 0.80 | 0.71 | 0.52 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -27.0% | - | -9.1% | -30.3% | 7.1% | - | -12.1% | -10.9% | -41.1% | - |
| Net income growth (YoY) | -33.3% | - | 20.5% | 61.9% | 6.8% | - | 39.5% | -74.3% | 17.4% | - |
| EPS growth (YoY) | 52.2% | - | 80.8% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -19.8% | - | - | - | 3.8% | - | - | - | -33.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 602.9% | 201.4% | 87.2% | -49.5% | -86.5% | -64.1% | -35.6% | -79.1% | 108.7% | 241.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GENOCEA BIOSCIENCES against the 5 most active filers in the same SIC group.